Pfizer Inc. and BioNTech have submitted a request to the European drug regulator for the approval of their coronavirus vaccine to be extended to include children 12 to 15 years old, in a move that could offer younger and less at-risk populations in Europe access to the shot for the first time.
In a statement Friday, the two pharmaceuticals said their submission to the European Medicines Agency is based on an advanced study in more than 2,000 adolescents that showed
This story was originally published on CBC News. To read the rest of this news worthy story, please visit https://www.cbc.ca/news/health/pfizer-biontech-europe-adolescents-1.6008644?cmp=rss.